CoChat

Sleep Laboratory Studies of Hypnotic Drugs: Efficacy and Withdrawal Effects

KALES, ANTHONY, KALES, JOYCE D. · 1983 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record.

Abstract

Flurazepam, temazepam, and triazolam are compared in terms of initial and short term efficacy, effectiveness during intermediate and long term use, withdrawal effects, and general side effects. The usefulness of temazepam is considerably restricted since the drug is slowly absorbed; peak blood concentrations are not reached until 2 to 3 hours after ingestion. Consequently, while the majority of insomniac patients complain primarily of difficulty falling asleep, temazepam is not effective for this sleep complaint. Further, the drug has an intermediate elimination half-life and induces a significant degree of morning sleepiness (hang-over). Rebound insomnia of a moderate degree occurs with some frequency following withdrawal of temazepam. Triazolam is effective initially and with short term use both for inducing and maintaining sleep. However, much of this effectiveness is lost with continued nightly use over an intermediate period (2 weeks). The drug has a rapid elimination rate; during drug administration, sleep may worsen in the final hours of the night (early morning insomnia), and following drug withdrawal, rebound insomnia is frequent, immediate, and severe. Side effects are frequent and include some morning sleepiness (before tolerance develops) and significant memory impairment and even episodes of amnesia. Triazolam may have a narrow margin of safety in that serious behavioral symptoms have been reported even with a 1-mg dose. Flurazepam is effective both for initiating and maintaining sleep with initial and short term drug administration. Further, its efficacy is maintained not only with intermediate term use but with long term drug use (4 weeks). Flurazepam is a long elimination half-life drug, and there is significant daytime sedation during short term use; with continued use this effect diminishes. Rebound insomnia has not been noted following withdrawal of flurazepam; there is a carry-over effectiveness into the first and second nights of withdrawal, and any withdrawal sleep disturbance would be expected to be infrequent, delayed in appearance, and mild in degree.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004714-198304000-00038

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 61

Metadata

Authors
KALES, A., & KALES, J. D.
Affiliations
Pennsylvania State University (US)
Venue
Journal of Clinical Psychopharmacology
Published
1983-04
Volume
3
Issue
2
Pages
140
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2045912535
Cited by
61
References
0
Citations by year
2023: 2 · 2015: 1 · 2013: 1 · 2012: 2
FWCI
3.88
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
hypnotics, flurazepam, temazepam, triazolam, rebound insomnia, drug withdrawal effects, insomnia, sleep maintenance, daytime sedation, memory impairment, adverse drug reactions, elimination half-life, drug absorption
MeSH terms
Antidepressive Agents, Tricyclic, Anxiety, Dose-Response Relationship, Drug, Flurazepam, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Sleep, Substance Withdrawal Syndrome, Temazepam, Anti-Anxiety Agents, Triazolam

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sleep Laboratory Studies of Hypnotic Drugs: Efficacy and Withdrawal Effects. https://app.cochat.ai/papers/10.1097/00004714-198304000-00038
The paper
KALES, A., & KALES, J. D. (1983). Sleep Laboratory Studies of Hypnotic Drugs: Efficacy and Withdrawal Effects. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198304000-00038

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.